AI Article Synopsis
- A new initiative in France introduced pharmaceutical consultations for patients diagnosed with digestive cancer receiving intravenous chemotherapy, aimed at enhancing patient management and support during treatment.
- Forty-seven consultations were conducted, averaging 39.3 minutes each, scheduled shortly after diagnosis and before the start of chemotherapy, with high patient satisfaction reported through a survey.
- These consultations provided valuable information on treatment and side effects, helping patients improve their self-care skills and understand their therapy better.
Article Abstract
Introduction: The announcement of a cancer diagnosis is traumatic for the patient. In France, an announcement system has been in place, providing medical time for announcement and treatment proposal, nursing time for support, without including the pharmacist. In order to improve management of patients treated with intravenous anticancer drugs, we set up introductory pharmaceutical consultations in digestive oncology. The aims were to assess the situation one year after the introduction of these consultations, and to assess their contribution.
Methods: When a patient was diagnosed with digestive cancer and receiving intravenous treatment, a pharmaceutical initiation consultation was scheduled. Indicators of activity (number of consultations, average duration, average preparation time and various delays) and results (number and type of pharmaceutical interventions, patient satisfaction) were collected in order to assess activity.
Results: Forty-seven pharmaceutical initiation consultations were carried out. The average duration of the consultations was 39.3minutes. Consultations were carried out on average 12.1 days after the medical consultation and 9.6 days before the first chemotherapy treatment. Twenty-nine patients responded to the satisfaction questionnaire. All were satisfied, and the majority of patients said they had improved their knowledge of cancer treatment.
Discussion: This activity enables us to review with patients essential aspects of their care, such as implanting an implantable chamber catheter, anti-cancer treatment and managing potential side effects and improve their self-care skills.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2024.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background And Objectives: Generic formulations of glatiramer acetate have been available since 2015 yet remain underprescribed relative to the branded product. We sought to characterize the association between branded glatiramer prescribing in the Medicare program and financial payments from the manufacturer (Teva Pharmaceuticals).
Methods: Using publicly available Medicare Part D and Open Payments data from the Centers for Medicare and Medicaid Services, we evaluated overall utilization from 2012 to 2021 and compared the prevalence, frequency, and magnitude of financial payments made in 2019 to neurologists who prescribed branded and generic versions of glatiramer in 2020.
Low-Dose Acyclovir Reduces the Reactivation of Herpes Simplex and Varicella Zoster Viruses After Allogeneic Stem Cell Transplantation.
Cureus
December 2024
Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, USA.
Introduction: Reactivation of herpes simplex virus (HSV) and varicella zoster virus (VZV) is a potential complication following allogeneic stem cell transplantation (alloSCT). Since different doses and durations of acyclovir prophylaxis may be utilized across transplant centers, this study aimed to evaluate the effectiveness of a lower dose of acyclovir in preventing HSV and VZV reactivation in alloSCT recipients within our institution.
Methods: A retrospective chart review was conducted for patients who underwent alloSCT between April 2016 and May 2023.
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.
Ther Adv Med Oncol
January 2025
Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease that is frequently associated with a host of known oncogenic alterations. Advances in molecular diagnostics and drug development have facilitated the targeting of novel alterations such that the majority of NSCLC patients have driver mutations that are now clinically actionable. The goal of this review is to gain insights into clinical research and development principles by summary, analysis, and discussion of data on agents targeting known alterations in oncogene-driven, advanced NSCLC beyond those in the and the .
View Article and Find Full Text PDFWho will benefit from vorasidenib? Review of data from the literature and open questions.
Neurooncol Pract
February 2025
Department of Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, California, USA.
The clinical efficacy of isocitrate dehydrogenase (IDH) inhibitors in the treatment of patients with grade 2 IDH-mutant (mIDH) gliomas is a significant therapeutic advancement in neuro-oncology. It expands treatment options beyond traditional radiation therapy and cytotoxic chemotherapy, which may lead to significant long-term neurotoxic effects while extending patient survival. The INDIGO study demonstrated that vorasidenib, a pan-mIDH inhibitor, improved progression-free survival for patients with grade 2 mIDH gliomas following surgical resection or biopsy compared to placebo and was well tolerated.
View Article and Find Full Text PDFSymptom management in isocitrate dehydrogenase mutant glioma.
Neurooncol Pract
February 2025
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!